Biofrontera Inc Market Cap ($13.22 Million)
Market Cap & Net Worth: Biofrontera Inc (BFRI)
Biofrontera Inc market cap. Biofrontera Inc (NASDAQ:BFRI) has a market capitalization of $13.22 Million ($13.22 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26196 globally and #5501 in its home market, demonstrating a 8.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofrontera Inc's stock price $0.89 by its total outstanding shares 14852359 (14.85 Million). Also see how efficiently does Biofrontera Inc generate cash for how efficiently the company converts equity into cash flow.
Biofrontera Inc Market Cap History (2021–2026)
Biofrontera Inc market cap history from 2021 to 2026. Data shows change from $2.23 Billion to $13.22 Million (-60.00% CAGR). Check latest Biofrontera Inc stock price today for real-time trading data and today's change.
Index Memberships
Biofrontera Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #732 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2395 of 3165 |
Weight: Biofrontera Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biofrontera Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofrontera Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Biofrontera Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.20x
Biofrontera Inc's market cap is 0.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.23 Billion | $24.10 Million | -$37.71 Million | 92.69x | N/A |
| 2022 | $272.39 Million | $28.67 Million | -$640.00K | 9.50x | N/A |
| 2023 | $41.14 Million | $34.07 Million | -$20.13 Million | 1.21x | N/A |
| 2024 | $16.19 Million | $37.30 Million | -$17.76 Million | 0.43x | N/A |
| 2025 | $8.47 Million | $41.70 Million | -$10.54 Million | 0.20x | N/A |
Competitor Companies of BFRI by Market Capitalization
Companies near Biofrontera Inc in the global market cap rankings as of November 4, 2026. Also see Biofrontera Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Biofrontera Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Biofrontera Inc (2021–2026)
Market capitalization of Biofrontera Inc from 2021 to today. Between 2021 and today, Biofrontera Inc's market cap moved from $2.23 Billion to $ 13.22 Million, with a yearly change of -60.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.22 Million | +56.12% |
| 2025 | $8.47 Million | -47.71% |
| 2024 | $16.19 Million | -60.65% |
| 2023 | $41.14 Million | -84.90% |
| 2022 | $272.39 Million | -87.81% |
| 2021 | $2.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Biofrontera Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.22 Million USD |
| MoneyControl | $13.22 Million USD |
| MarketWatch | $13.22 Million USD |
| marketcap.company | $13.22 Million USD |
| Reuters | $13.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more